Safety of Levodopa-Carbidopa Intestinal Gel Treatment in Patients with Advanced Parkinson’s Disease Receiving ≥2000 mg Daily Dose of Levodopa

Background. Levodopa-carbidopa intestinal gel (LCIG) provides continuous levodopa administration and clinical benefits to patients with advanced Parkinson’s disease (PD). This report evaluates long-term safety and efficacy of high-dose LCIG in PD patients. Methods. Data were collected from several p...

Full description

Saved in:

Bibliographic Details
Published in:	Parkinson's disease Vol. 2020; no. 2020; pp. 1 - 11
Main Authors:	Antonini, Angelo, Benesh, Janet, Kukreja, Pavnit, Ijacu, Horia, Bergmann, Lars, Boyd, James T., Poewe, Werner, Zadikoff, Cindy, Robieson, Weining Z.
Format:	Journal Article
Language:	English
Published:	Cairo, Egypt Hindawi Publishing Corporation 2020 Hindawi John Wiley & Sons, Inc Wiley
Subjects:	Carbidopa Clinical trials Complications and side effects Datasets Demography Dopa Dopamine Dosage Double-blind studies Drug dosages Dyskinesia Intestine Levodopa Medical research Medicine, Experimental Movement disorders Neurodegenerative diseases Parkinson's disease Patients Pharmaceutical industry Polyneuropathy Quality of life Safety Safety and security measures Studies United States United States > US
ISSN:	2090-8083, 2042-0080
Online Access:	Get full text
Tags:	Add Tag No Tags, Be the first to tag this record!

Be the first to leave a comment!